Skip to content

Perlara

YC W16 · Active · Perlara: building the YC for rare disease parents

Competitors

Adjacent

Also from W16

All of W16

About Perlara

Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech

YC batch
W16 · Winter 2016
Status, per YC
Active
Category
Other
Team size
1
Location
San Francisco, CA, USA; Oakland, CA, USA; Remote
Checked
33m ago

Perlara in W16: 122 companies, 18% AI

Perlara: questions

Which YC batch was Perlara in?

Perlara was in Y Combinator's Winter 2016 batch (W16).

Is Perlara still active?

Y Combinator lists Perlara as active.

Where is Perlara based?

Perlara lists San Francisco, CA, USA; Oakland, CA, USA; Remote as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.